MedTrace Logo

Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia

NCT07605845 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-05-26

No results posted yet for this study

Summary

The goal of this clinical trial is to demonstrate GL-2045 safety and efficacy proof of concept by demonstrating intravenous immunoglobulin (IVig)-like platelet responses in adult patients with Immune Thrombocytopenia (ITP).

Conditions

Interventions

DRUG

GL-2045

Administrative route: SC injection

Sponsors & Collaborators

  • Gliknik Inc.

    lead INDUSTRY

Principal Investigators

  • Jim Bush, MBChB, PhD · Fortrea Clinical Research Unit Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-14
Primary Completion
2027-12-06
Completion
2027-12-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07605845 on ClinicalTrials.gov